Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EXAS NASDAQ:ILMN NASDAQ:MYGN NASDAQ:NTRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXASExact Sciences$104.91$103.67$38.81▼$104.98$20.03B1.413.55 million shsN/AILMNIllumina$142.54-0.5%$128.58$78.55▼$155.53$21.57B1.421.67 million shs1.77 million shsMYGNMyriad Genetics$3.58-1.1%$4.65$3.57▼$8.59$338.12M1.811.59 million shs1.64 million shsNTRANatera$186.36-5.4%$200.83$131.81▼$256.36$26.69B1.571.52 million shs2.24 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXASExact Sciences0.00%0.00%0.00%+1.62%+91.20%ILMNIllumina0.00%+0.47%+7.40%+22.03%+82.25%MYGNMyriad Genetics0.00%-16.55%-28.40%-20.27%-6.77%NTRANatera0.00%-4.06%-4.97%-9.63%+23.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXASExact Sciences$104.91$103.67$38.81▼$104.98$20.03B1.413.55 million shsN/AILMNIllumina$142.54-0.5%$128.58$78.55▼$155.53$21.57B1.421.67 million shs1.77 million shsMYGNMyriad Genetics$3.58-1.1%$4.65$3.57▼$8.59$338.12M1.811.59 million shs1.64 million shsNTRANatera$186.36-5.4%$200.83$131.81▼$256.36$26.69B1.571.52 million shs2.24 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXASExact Sciences0.00%0.00%0.00%+1.62%+91.20%ILMNIllumina0.00%+0.47%+7.40%+22.03%+82.25%MYGNMyriad Genetics0.00%-16.55%-28.40%-20.27%-6.77%NTRANatera0.00%-4.06%-4.97%-9.63%+23.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEXASExact Sciences 1.95Reduce$92.13-12.19% DownsideILMNIllumina 2.28Hold$137.75-3.36% DownsideMYGNMyriad Genetics 2.00Hold$6.4078.77% UpsideNTRANatera 2.79Moderate Buy$256.6037.69% UpsideCurrent Analyst Ratings BreakdownLatest ILMN, NTRA, EXAS, and MYGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026ILMNIllumina Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$170.005/14/2026ILMNIllumina Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy5/14/2026ILMNIllumina Daiwa Securities GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Outperform$155.005/12/2026NTRANatera Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$249.005/11/2026NTRANatera BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$260.00 ➝ $250.005/8/2026NTRANatera Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$265.005/8/2026NTRANatera EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$270.005/8/2026NTRANatera JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$260.00 ➝ $265.005/8/2026NTRANatera Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$215.00 ➝ $220.005/6/2026MYGNMyriad Genetics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$7.00 ➝ $6.005/6/2026MYGNMyriad Genetics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$6.00 ➝ $5.50(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEXASExact Sciences$3.25B6.17$1.27 per share82.83$12.58 per share8.34ILMNIllumina$4.34B4.97$6.71 per share21.23$17.69 per share8.06MYGNMyriad Genetics$824.50M0.41$3.77 per share0.95$3.57 per share1.00NTRANatera$2.31B11.57N/AN/A$12.39 per share15.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEXASExact Sciences-$207.95M-$1.10N/A209.822.02-6.40%0.53%0.22%N/AILMNIllumina$850M$5.5025.9224.242.3619.42%31.01%12.22%7/30/2026 (Estimated)MYGNMyriad Genetics-$365.90M-$4.30N/AN/AN/A-48.24%-8.51%-4.48%8/4/2026 (Estimated)NTRANatera-$208.16M-$1.63N/A745.44N/A-9.05%-14.74%-10.27%N/ALatest ILMN, NTRA, EXAS, and MYGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026MYGNMyriad Genetics-$0.06-$0.09-$0.03-$0.36$202.42 million$200.40 million4/30/2026Q1 2026ILMNIllumina$1.05$1.15+$0.10$0.87$1.07 billion$1.09 billion2/26/2026Q4 2025NTRANatera-$0.46$0.35+$0.81$0.36$600.68 million$665.50 million2/23/2026Q4 2025MYGNMyriad Genetics-$0.02$0.04+$0.06-$0.08$207.57 million$209.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEXASExact SciencesN/AN/AN/AN/AN/AILMNIlluminaN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ANTRANateraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEXASExact Sciences0.972.432.17ILMNIllumina0.561.751.36MYGNMyriad Genetics0.362.402.19NTRANateraN/A2.963.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEXASExact Sciences88.82%ILMNIllumina89.42%MYGNMyriad Genetics99.02%NTRANatera99.90%Insider OwnershipCompanyInsider OwnershipEXASExact Sciences1.20%ILMNIllumina2.90%MYGNMyriad Genetics1.90%NTRANatera5.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEXASExact Sciences7,200190.89 million188.60 millionOptionableILMNIllumina8,650151.30 million146.91 millionOptionableMYGNMyriad Genetics2,70094.45 million92.65 millionOptionableNTRANatera6,140143.21 million135.15 millionOptionableILMN, NTRA, EXAS, and MYGN HeadlinesRecent News About These CompaniesSignateraâ„¢ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)May 15 at 1:01 PM | businesswire.comNatera, Inc. (NASDAQ:NTRA) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 13, 2026 | americanbankingnews.comNatera, Inc. (NASDAQ:NTRA) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 13, 2026 | marketbeat.comNTRA Q1 Deep Dive: Robust Volume Growth and Product Expansion Shape OutlookMay 12, 2026 | uk.finance.yahoo.comNatera (NASDAQ:NTRA) Given New $250.00 Price Target at BTIG ResearchMay 12, 2026 | americanbankingnews.comAssessing Natera (NTRA) Valuation After Recent Share Price Pullback And Long Term ReturnsMay 11, 2026 | finance.yahoo.comNatera (NTRA) Is Up 6.6% After Record Q1 Revenue But Wider Losses - Has The Bull Case Changed?May 11, 2026 | finance.yahoo.comBTIG Research Has Lowered Expectations for Natera (NASDAQ:NTRA) Stock PriceMay 11, 2026 | marketbeat.comC WorldWide Group Holding A S Has $31.61 Million Stock Holdings in Natera, Inc. $NTRAMay 11, 2026 | marketbeat.comAubrey Capital Management Ltd Grows Stock Holdings in Natera, Inc. $NTRAMay 11, 2026 | marketbeat.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for Natera (NASDAQ:NTRA) StockMay 10, 2026 | americanbankingnews.comNatera, Inc. (NTRA) Q1 2026 Earnings Call TranscriptMay 9, 2026 | seekingalpha.comNatera NTRA Q1 2026 Earnings Call TranscriptMay 9, 2026 | finance.yahoo.comNatera: Q1 Earnings SnapshotMay 9, 2026 | chron.comNatera’s (NASDAQ:NTRA) Q1 CY2026 sales top estimatesMay 9, 2026 | msn.comWhy Natera (NTRA) shares are plunging todayMay 9, 2026 | msn.comNatera (NASDAQ:NTRA) Cut to "Hold" at Wall Street ZenMay 9, 2026 | marketbeat.comNatera (NASDAQ:NTRA) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst SaysMay 8, 2026 | marketbeat.comNatera (NASDAQ:NTRA) Trading Down 9.5% Following Weak EarningsMay 8, 2026 | marketbeat.comWells Fargo & Company Forecasts Strong Price Appreciation for Natera (NASDAQ:NTRA) StockMay 8, 2026 | marketbeat.comTruist Financial Corp Has $11.81 Million Holdings in Natera, Inc. $NTRAMay 8, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThese 3 Defense Giants Beat Q1 Estimates—So Why Did Their Stocks Still Fall?By Jessica Mitacek | April 22, 2026Industrial Chips Are in Rally Mode—5 Ways to PlayBy Thomas Hughes | April 27, 2026Corning Beats Q1 Estimates but Drops 9% on Guidance MissBy Ryan Hasson | April 29, 2026Microsoft Targets Trimmed: What It Means for InvestorsBy Chris Markoch | April 20, 2026Up 775% in 5 Months, How Much Higher Can Syntec Optics Go?By Thomas Hughes | April 21, 2026ILMN, NTRA, EXAS, and MYGN Company DescriptionsExact Sciences NASDAQ:EXASExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Illumina NASDAQ:ILMN$142.54 -0.70 (-0.49%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$140.32 -2.22 (-1.55%) As of 05/15/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.Myriad Genetics NASDAQ:MYGN$3.58 -0.04 (-1.10%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$3.66 +0.08 (+2.21%) As of 05/15/2026 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Natera NASDAQ:NTRA$186.36 -10.55 (-5.36%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$192.74 +6.38 (+3.43%) As of 05/15/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware Viking Sails to All-Time Highs—Fundamentals Signal More to Come YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
